0.05Open0.05Pre Close0 Volume1 Open Interest1.00Strike Price0.00Turnover521.61%IV84.60%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type-0.0137Delta0.0052Gamma123.40Leverage Ratio-0.0072Theta-0.0001Rho-1.70Eff Leverage0.0005Vega
Recursion Pharmaceuticals Stock Discussion
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
• First program to combine Recursion's end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months
• Plan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient po...
Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-in-Class Rbm39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma
She makes millionaires out of her clients, they all started as multimillionaires.
if you think the AI story is just getting started, this is one field you must watch... it's a hugely...
1. Autonomous vehicles: Nvidia has invested in companies like DeepMap, Zoox, and Aurora Innovation.
2. Artificial intelligence: Nvidia has invested in companies like Element AI, (link unavailable), and Graphcore.
3. Healthcare: Nvidia has invested in companies like Owkin and Recursion Pharmaceuticals.
4. Robotics: Nvidia has invested in companies like Fetch Robotics and Nuro.
they just needed a catalyst from rate cuts and this expectation is enough to tr...
No comment yet